Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, The Brigham And Women’S Hospital IncfiledCriticalPfizer
Publication of AR109825A1publicationCriticalpatent/AR109825A1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Peptides Or Proteins
(AREA)
Abstract
La presente se relaciona con anticuerpos, o fragmentos de los mismos de enlace al antígeno, que de manera específica enlazan el interferón b (IFNb). Dichos anticuerpos, o fragmentos de los mismos de enlace al antígeno, son útiles para varios propósitos terapéuticos o de diagnóstico. Ácido nucleico; vector; célula huésped; composición farmacéutica; método.This is related to antibodies, or fragments thereof binding to the antigen, that specifically bind interferon b (IFNb). Such antibodies, or fragments thereof binding to the antigen, are useful for various therapeutic or diagnostic purposes. Nucleic acid; vector; host cell; pharmaceutical composition; method.
ARP170101100A2016-04-292017-04-28
INTERFERON ANTIBODIES b AND USES OF THE SAME
AR109825A1
(en)
anti-il-33 neutralizing human monoclonal antibody, pharmaceutical composition, cytokine expression inhibitor, epitope, nucleic acid molecule, vector, host cell, method of production and use thereof.
bispecific antibody, antibodies, pharmaceutical composition, use of bispecific antibody, nucleic acid sequence, expression vector, prokaryotic or eukaryotic host cell, and method of producing an antibody